Praluent® – Alirocumab Injection

Praluent® – Alirocumab Injection | 75mg/mL or 150mg/mL | U.S.-Manufactured Global Supply

Product Overview

Praluent® (Alirocumab) is a human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), used to lower LDL-C levels in patients with hypercholesterolemia, familial hypercholesterolemia (HeFH), or clinical atherosclerotic cardiovascular disease (ASCVD). Co-developed by Regeneron and Sanofi, Praluent is part of a new class of PCSK9 inhibitors proven to reduce cardiovascular risk when added to statin therapy.

This listing includes 75mg/mL and 150mg/mL pre-filled syringes or pens, suitable for subcutaneous self-injection every 2 weeks or monthly depending on dosage. Product is manufactured in the United States and sourced through the global pharmaceutical supply chain, with export-ready labeling.

📘 For detailed clinical trials, see PubMed – Alirocumab Studies

---

Key Features & Benefits

• ✅ PCSK9 Inhibition for LDL Reduction
  Praluent prevents PCSK9 from binding LDL receptors, thereby enhancing LDL clearance from the bloodstream.

• ✅ Proven Cardiovascular Risk Reduction
  In the ODYSSEY OUTCOMES trial, Praluent significantly reduced the risk of MI, stroke, and unstable angina in high-risk patients.

• ✅ Flexible Dosing Options

  • 75mg/mL – Standard LDL-C control

  • 150mg/mL – For patients requiring intensive lipid-lowering

• ✅ Patient-Friendly Delivery System
  Offered in pre-filled pens or pre-filled syringes for at-home administration with minimal discomfort.

• ✅ US-Manufactured, Global Label Variant
  Identical formulation to U.S. domestic version; only label language differs to meet global regulatory needs.

---

Product Specifications

• Product Name: Praluent® (Alirocumab)

• Strengths Available: 75 mg/mL or 150 mg/mL

• Dosage Form: Injection, subcutaneous

• Device Type: Pre-filled syringe or autoinjector pen

• Origin: United States

• Packaging: 1 or 2 pens/syringes per carton (varies by region)

• Storage: Refrigerated at 2°C – 8°C

• Shelf Life: 18–24 months (depending on lot)

• Use Frequency: Every 2 weeks or monthly (as per clinical protocol)

---

Recommended Indications

• Adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH)

• Patients with clinical ASCVD who require additional LDL-C lowering beyond statins

• Individuals intolerant to statins or unable to achieve lipid goals with oral therapy alone

---

How It Works

Alirocumab is a fully human IgG1 monoclonal antibody that binds to circulating PCSK9, preventing it from degrading LDL receptors on hepatocytes. This enhances the liver’s ability to remove LDL cholesterol, leading to dose-dependent reductions in LDL-C levels—often exceeding 50% when combined with statins.

📘 Learn more at FDA Label Information for Praluent

---

Compliance Statement

This product is manufactured in the United States and supplied through a global pharmaceutical distribution channel. Intended strictly for licensed healthcare professionals and institutional buyers. Product labeling and language may differ to meet destination country regulations. All importers and end users must comply with local laws governing monoclonal antibody therapeutics.

---

Tags / Keywords

Praluent Alirocumab Injection, PCSK9 Inhibitor Monoclonal Antibody, LDL Cholesterol Reducer, Praluent Global Supply, 75mg 150mg PCSK9, Sanofi Regeneron Praluent, Hyperlipidemia Injectable Treatment, US Export Biologic, Praluent PFS Pen